Subscribe to RSS
DOI: 10.1055/a-2551-0724
Hepatic stellate cells functional heterogeneity in liver cancer
Supported by: Agencia Estatal de Investigación PID2021-123652OB-I00,PID2021-124694OA-I00,PID2022-141984OB-I00 ,RYC2021-034121-I,RYC2022-036321-ISupported by: American Cancer Society RSG-22-061-01-MM
Supported by: European Research Council 101077312
Supported by: NIH 1R01DK133512
Supported by: NIH/NCI P30 CA008748
Supported by: Pfizer Foundation 77131383

Hepatic stellate cells (HSCs) are the liver’s pericytes, and play key roles in liver homeostasis, regeneration, fibrosis and cancer. Upon injury, HSCs activate and are the main origin of myofibroblasts and cancer associated fibroblasts (CAFs) in liver fibrosis and cancer. Primary liver cancer has a grim prognosis, ranking as the 3rd leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the predominant type, followed by intrahepatic cholangiocarcinoma (iCCA). Moreover, the liver hosts 35% of all metastatic lesions. The distinct spatial distribution and functional roles of HSCs across these malignancies represent a significant challenge for universal therapeutic strategies, requiring a nuanced and tailored understanding of their contributions. This review examines the heterogeneous roles of HSCs in liver cancer, focusing on their spatial localization, dynamic interactions within the tumor microenvironment (TME), and emerging therapeutic opportunities, including strategies to modulate their activity, and harness their potential as targets for anti-fibrotic and anti-tumor interventions.
Publication History
Received: 12 December 2024
Accepted after revision: 04 March 2025
Accepted Manuscript online:
05 March 2025
© . Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA